Overview

This evening symposium will be held in conjunction with the AARC Congress 2016. Idiopathic pulmonary fibrosis (IPF) is a rare, progressive lung disease that greatly impacts patients’ quality of life and diminishes life expectancy. New therapies are available that slow lung function decline. These therapies are used in combination with oxygen supplementation, pulmonary rehabilitation, symptomatic treatment, and supportive care. Respiratory therapists need education on the new therapies and supportive care to educate and counsel patients with IPF, as well as optimize their care.

This activity is intended for respiratory therapists and other clinicians at the AARC Congress involved in the management of patients with IPF.

Upon completion of this activity, participants will be able to:
• Outline the prevalence, signs and symptoms, and diagnostic criteria for IPF
• Compare and contrast available therapies for IPF
• Formulate strategies for comprehensive management of symptoms
• Effectively counsel IPF patients on available therapies and supportive care
• Identify patients with IPF who may benefit from intensification of therapy

Grand Hyatt San Antonio
600 E. Market St.
Texas Ballroom, Salons D-E (4th Floor)
San Antonio, TX 78205 USA
Click here to view location map

Sponsored by the Academy for Continued Healthcare Learning.

This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.